Table 1.
Baseline characteristics in CTEPH and control groups
| CTEPH group
|
Control group
|
|||
|---|---|---|---|---|
| Male (n=33) | Female (n=40) | Male (n=25) | Female (n=10) | |
| Baseline characteristics | ||||
| Age, years | 62.5±13.4 | 61.5±11.8 | 60.2±6.5 | 60.6±6.7 |
| BMI, kg/m2 | 23.7±2.8 | 23.1±2.6 | 23.9±2.6 | 24.4±3.4 |
| 6MWD, m | 384.2±116.6 | 370.9±89.4 | – | – |
| NT-proBNP, pg/mL | 1,077 (435, 1,989) | 634 (75, 2,238) | – | – |
| WHO FC, n (%) | ||||
| I–II | 10 (30.3) | 13 (32.5) | – | – |
| III–IV | 21 (63.6) | 24 (60.0) | – | – |
| Hemodynamics | ||||
| mRAP, mmHg | 5.4±4.3 | 6.3±4.8 | – | – |
| mPAP, mmHg | 46.3±11.1 | 45.7±10.9 | – | – |
| mPAWP, mmHg | 8.4±3.4 | 7.6±3.3 | – | – |
| PVR, Wood units | 8.3±4.3 | 8.6±3.8 | – | – |
| CO, L/min | 4.9±1.2 | 4.6±1.5 | – | – |
| CI, L/min/m2 | 2.8±0.6 | 2.9±0.9 | – | – |
| Specific medications | ||||
| PDE-5 inhibitors, % | 12 (36.4) | 13 (32.5) | ||
| ERAs, % | 1 (3.0) | 2 (5.0) | ||
| Prostacyclin analogs, % | 3 (9.1) | 5 (12.5) | ||
| Combination, % | 11 (33.3) | 16 (40.0) | ||
| Nonspecific medication, % | 6 (18.2) | 4 (10.0) | ||
Notes: Values are mean (SD), median (interquartile range), or n (%).
Abbreviations: 6MWD, 6-minute walk distance; BMI, body mass index; CI, cardiac index; CO, cardiac output; CTEPH, chronic thromboembolic pulmonary hypertension; ERA, endothelial receptor antagonist; mPAP, mean pulmonary arterial pressure; mPAWP, mean pulmonary capillary wedge pressure; mRAP, mean right atrial pressure; NT-proBNP, N-terminal pro-brain natriuretic peptide; PDE-5, phosphodiesterase type 5; PVR, pulmonary vascular resistance; WHO FC, World Health Organization Functional Class.